1795P China ARCHES: A multicenter phase III randomized double-blind placebo (PBO)-controlled efficacy and safety trial of enzalutamide (ENZA) + androgen deprivation therapy (ADT) vs PBO + ADT in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)

In the global ARCHES trial (NCT02677896), ENZA + ADT improved overall survival and radiographic progression-free survival (rPFS) vs PBO + ADT in pts with mHSPC. The China ARCHES trial evaluated the efficacy and safety of ENZA + ADT vs PBO + ADT in Chinese pts with mHSPC.